{"nctId":"NCT01658995","briefTitle":"Management of Etonogestrel Subdermal Implant-related Bleeding","startDateStruct":{"date":"2012-09-13","type":"ACTUAL"},"conditions":["ESI-related Bleeding"],"count":82,"armGroups":[{"label":"Post ESI implant - Doxycycline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Doxycycline"]},{"label":"Post ESI implant - Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Doxycycline","otherNames":["Adoxa, Alodox, Avidoxy, Bio-Tab, Doryx, Doxy Lemmon, Doxy-Caps, Monodox, Morgidox, Ocudox, Oracea, Oraxyl, Periostat, Vibra-Tabs, Vibramycin"]},{"name":"Placebo","otherNames":["Sugar pill"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Premenopausal women, aged 18-51 years\n* Expressed desire for compliance-independent contraception\n* No current pregnancy or anticipated desire for childbearing within 3 years of study enrollment and Implanon insertion\n* Agreement to participate in all study related procedures and evaluations as documented by a signed informed consent\n\nExclusion Criteria:\n\n* Current or prior use of Implanon\n* Current long-term use of Doxycycline for other indications\n* Known structural uterine abnormalities such as polyp, submucosal leiomyoma\n* Prior permanent sterilization or endometrial ablation\n* Pregnancy or desire for childbearing within 3 years\n* Contraindications to or intolerance of etonogestrel\n* Allergy to or intolerance of Doxycycline\n* Inability or unwillingness to complete study related procedures and evaluations","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"51 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Secondary Treatment","description":"The proportion of subjects who requested additional secondary treatment of intervention after ESI","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Subject Satisfaction","description":"Number of subjects who reported satisfaction with bleeding after 13 weeks post ESI insertion. As measured by the number of subjects answering very satisfied or satisfied on the Patient Satisfaction Survey question \"To what extent have you been satisfied overall while using the contraceptive implant? Very satisfied, satisfied, neither satisfied or dissatisfied, dissatisfied or very dissatisfied.\"","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Removal of ESI","description":"Number of subjects who requested ESI removal","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":42},"commonTop":[]}}}